Screener
Boston Scientific BSX Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
| (in millions, except share and per share data) | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Treasury stock, at cost - 263,289,848 shares as of March 31, 2026 and December 31, 2025 | (2,251) | (2,251) |
| Additional paid-in capital | 21,584 | 21,505 |
| Retained earnings | 6,912 | 5,571 |
| Accumulated other comprehensive income (loss), net of tax | (398) | (610) |
| Total stockholders’ equity | 25,864 | 24,233 |
| Noncontrolling interests | 240 | 239 |
| Total equity | 26,104 | 24,472 |
| TOTAL LIABILITIES AND EQUITY | $44,351 | $43,673 |
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's noncontrolling interests in subsidiaries?
- Boston Scientific (BSX) reported noncontrolling interests in subsidiaries of $240M in Q1 2026.
- How has Boston Scientific's noncontrolling interests in subsidiaries changed year-over-year?
- Boston Scientific's noncontrolling interests in subsidiaries increased by 3.0% year-over-year, from $233M to $240M.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.
Ask your AI about Boston Scientific's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude